Related Experiment Videos
[FK506 (tacrolimus) does not increase hepatic damage due to hypoperfusion]
R Ben Abraham1, I Isartal, R Nakache
1Dept. of Anesthesiology and Critical Care Medicine, Tel Aviv-Sourasky Medical Center, Tel Hashomer.
Harefuah
|July 7, 2000
Summary
Tacrolimus (Prograf) did not worsen liver dysfunction after hypoperfusion in a rat model. This suggests tacrolimus may be safer than cyclosporin A during the perioperative period for liver transplant patients.
Area of Science:
- Immunosuppression in transplantation
- Hepatology
- Pharmacology
Context:
- Liver transplantation is a life-saving procedure but carries risks of hepatic dysfunction.
- Cyclosporin A, a common immunosuppressant, can exacerbate liver damage, particularly after hypoperfusion.
- Tacrolimus (Prograf) is a newer immunosuppressant with a potentially better safety profile.
Purpose:
- To evaluate the impact of tacrolimus on hepatocellular damage and oxygen extraction in an ex-vivo rat liver perfusion model following hypoperfusion.
- To compare the safety of tacrolimus versus cyclosporin A in the context of perioperative liver hypoperfusion.
Summary:
- An ex-vivo rat liver model was used to assess the effects of tacrolimus administration after induced liver hypoperfusion.
- Hepatocellular damage and oxygen extraction were measured to determine the drug's impact on liver function.
- Results indicated that tacrolimus did not exacerbate the hepatic dysfunction caused by hypoperfusion.
Impact:
- Tacrolimus may offer a safer alternative to cyclosporin A for immunosuppression in the perioperative period of liver transplantation.
- Findings suggest that tacrolimus's use could mitigate risks associated with liver hypoperfusion-induced organ dysfunction.
- This research contributes to optimizing immunosuppressive strategies in liver transplant recipients.